ClearPoint Neuro, Inc.

NCM: CLPT
Live Quote

📈 ZcoreAI Score

Our AI model analyzes ClearPoint Neuro, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get CLPT Z-Score →

About ClearPoint Neuro, Inc.

Healthcare Medical Devices
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

📊 Fundamental Analysis

ClearPoint Neuro, Inc. demonstrates a profit margin of -69.1%, which is below the sector average, suggesting competitive pressure.

The company recently reported 34.0% revenue growth, which is well above average for the Healthcare sector.

Return on Equity (ROE) is -95.6%, which indicates that capital utilization is currently under pressure.

At a current price of $8.68, CLPT currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $8.27 - $30.10).

🏥 Financial Health

🔴 Profit Margin Weak
🔴 Debt/Equity Elevated
Revenue Growth Excellent
🔴 Return on Equity Weak
⚠️ Beta (Risk) Moderate Volatility

Key Financials

Market Cap
$258.22M
Trailing P/E
--
Forward P/E
-10.65
Beta (5Y)
1.18
52W High
$30.10
52W Low
$8.27
Avg Volume
806K
Day High
Day Low
Get CLPT Z-Score on Dashboard 🚀